‘We’re targeting the biggest causes of age-related morbidity and mortality’

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Rubedo’s new CEO discusses the potential for senolytics in aging and healthspan as company gears up for clinical trials.

This week, senotherapeutics biopharma Rubedo Life Sciences announced the appointment of Dr Frederick Beddingfield as its new CEO. The biopharma industry veteran, most recently of longevity focused investment firm Apollo Health Ventures, takes over from Rubedo founder Dr Marco Quarta, who becomes the company’s Chief Scientific Officer.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE